SCHEMBL1618833

SCHEMBL1618833

CCc1c(Cl)ccnc1C(=O)NO[Si](C(C)C)(C(C)C)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
GRM4 Q14833 3/20 0.33
KMT2A Q03164 3/20 0.33
CTSA P10619 1/20 0.33
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.31
GAA P10253 1/20 0.31
MEN1 O00255 2/20 0.31
KDM4E B2RXH2 1/20 0.30
ASPH Q12797 1/20 0.30
KDM8 Q8N371 1/20 0.30
TSHR P16473 1/20 0.30
ALDH1A1 P00352 1/20 0.30
BRD4 O60885 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31587670 0.75 L3MBTL1 (0.43) KDM4CKMT2ACYP1A2CYP3A4L3MBTL1
SCHEMBL16465715 0.74 CDK8 (0.37) PRKCIKMT2ANPC1RAB9ACYP1A2
SCHEMBL18149947 0.73 KDM4E (0.41) KDM4CKMT2ACYP1A2CYP3A4L3MBTL1
SCHEMBL714506 0.71 ALDH1A1 (0.36) KMT2ANPC1RAB9AL3MBTL1GAA
SCHEMBL31116809 0.71 KDM4E (0.40) KDM4CKMT2ACYP1A2CYP3A4L3MBTL1
SCHEMBL15636734 0.63 PTGS2 (0.37) L3MBTL1KDM4EALDH1A1BRD4
SCHEMBL25779434 0.62 L3MBTL1 (0.42) KDM4CKMT2ACYP1A2L3MBTL1KDM4E
SCHEMBL18438840 0.61 L3MBTL1 (0.36) NPC1RAB9ACYP1A2CYP3A4L3MBTL1
SCHEMBL22863890 0.61 NOS2 (0.41) PRKCICYP3A4KDM4EALDH1A1
SCHEMBL16235570 0.61 ANO1 (0.48) ANO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928239-B2 Anticarcinogenic agents BAYER HEALTHCARE LLC (US) 2011-04-19 US disclosed
US-20020165394-A1 Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas BAYER CORPORATION 2002-11-07 US disclosed
CN-1341098-A Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER AG (US) 2002-03-20 CN disclosed
US-20010016659-A1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC 2001-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165394-A1 Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas BRAF, RAF1, ARAF PRKCI 238/4885KDM4C 1701/4885GRM4 4564/4885
US-20010016659-A1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BRAF, RAF1, ARAF PRKCI 113/4885KDM4C 1547/4885GRM4 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.